ライフサイエンスコーパス: adrenergic blocker

1 resence of prazosin (10 mumol/L), an alpha 1-adrenergic blocker.

2 giotensin-converting enzyme inhibitors, beta-adrenergic blockers, aldosterone antagonists, and digoxi

3 beta-adrenergic blockers, amiodarone, and sotalol are the mos

4 edications for CVD treatment, including beta-adrenergic blockers and ACE inhibitors, potentially exac

5 amate could be reversibly suppressed by beta-adrenergic blockers and the order of inhibitory potency

6 chieved using calcium-channel blockers, beta-adrenergic blockers, and class I or III antiarrhythmic d

7 beta-adrenergic blockers are still the most common medicine p

8 ors, angiotensin-receptor blockers, and beta-adrenergic blockers, are routinely used and are quite ef

9 Initial treatment included a beta-adrenergic blocker (beta-blocker) alone in 24%, a calciu

10 initially thought to be harmful in HF, beta-adrenergic blockers (beta-blockers) have consistently be

11 and in combination with propranolol (a beta-adrenergic blocker), both given systemically, to reduce

12 th limitation of sympathoadrenal activation, adrenergic blockers could prevent hypoglycemia-induced a

13 Nonselective beta-adrenergic blockers decrease portal pressure and prevent

14 ental conditions for SERS, we chose the beta-adrenergic blocker drug propranolol as the target analyt

15 , angiotensin-receptor blockers (ARBs), beta-adrenergic blockers, epinephrine, and Kounis syndrome.

16 tensin-converting enzyme inhibitors and beta-adrenergic blockers, has been shown to improve the long-

17 n addition, recent studies suggest that beta-adrenergic blockers have a beneficial effect on both sur

18 Thiazide diuretics, niacin, and beta-adrenergic blockers impair glucose homeostasis.

19 ar basis for the therapeutic actions of beta-adrenergic blockers in LQT1 and suggest that sodium chan

20 served with propranolol, a nonselective beta-adrenergic blocker, in pretreated animals such that the

21 Additionally, infusion of beta-adrenergic blockers into the amygdala blocks the memory-

22 patients with CHF who are treated with beta-adrenergic blockers is currently unknown.

23 evious reports that betaxolol and other beta-adrenergic blockers may exert its neuroprotective action

24 Combination of PDE5 inhibitors and alpha1-adrenergic blockers may have an additive beneficial effe

25 t-or-flight stress response such as the beta-adrenergic blocker metoprolol and the beta-adrenergic ag

26 Use of antianginal medications (beta-adrenergic blockers, nitrates, and calcium-channel block

27 he effectiveness of betaxolol and other beta-adrenergic blockers on glutamate-induced calcium signals

28 ed by alpha (prazosin)- or beta (propanolol)-adrenergic blockers or L-type Ca2+ channel blockers (ver

29 rged about the effectiveness of the alpha(1)-adrenergic blocker prazosin hydrochloride in the treatme

30 imulation by norepinephrine plus an alpha(1)-adrenergic blocker, prazosin, increased the amplitude of

31 months, 39% of patients were receiving beta-adrenergic blockers (preprocedure proportion, 43%; P < 0

32 , the centrally and peripherally acting beta-adrenergic blocker propranolol (4 or 10 mg/kg ip), or th

33 es were reversed by the addition of the beta-adrenergic blocker propranolol.

34 can be inhibited by the addition of the beta-adrenergic blocker propranolol.

35 greater after the administration of the beta-adrenergic blocker propranolol.

36 rom a mammalian host, we administered a beta-adrenergic blocker, propranolol, to infected mice.

37 In patients with myocardial infarction, beta-adrenergic blockers reduce recurrent myocardial infarcti

38 Prophylactic use of beta-adrenergic blockers reduces the incidence of postoperati

39 ion therapy using PDE5 inhibitors and alpha1-adrenergic blockers resulted in greater improvements in

40 Prophylactic treatment with beta-adrenergic blockers should be continued during the pregn

41 0 mg/kg ip), or the peripherally acting beta-adrenergic blocker sotalol (4 or 10 mg/kg ip) immediatel

42 of left ventricular assist devices and beta-adrenergic blockers suggest that attenuation of progress

43 Even at high doses, beta-adrenergic blockers, the first-line therapy, often are i

44 Long-term administration of beta-adrenergic blockers to patients after myocardial infarct

45 onic agents, alpha-adrenergic agonists, beta-adrenergic blockers, tricyclic or tetracyclic antidepres

46 The beta-adrenergic blocker was only effective when the drug was

47 Treatment with beta-adrenergic blockers was independently associated with a